drugset / Trial / NCT00309023
Study of BMS-663513 in Patients With Advanced Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a Phase I/II, ascending, multi-dose study of BMS-663513, an agonistic anti-CD137 monoclonal antibody, administered every three weeks to patients with metastatic or locally advanced solid tumors.
Timeline
- Start
- 2005-12
- Primary completion
- 2008-12
- Completion
- 2009-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Urelumab | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | Urelumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Urelumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Urelumab | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | Urelumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Urelumab | Monoclonal antibody | 15 mg/kg | Intravenous |